HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshiaki Sunazuka Selected Research

Macrolides

1/2020The non-antibiotic macrolide EM900 attenuates HDM and poly(I:C)-induced airway inflammation with inhibition of macrophages in a mouse model.
1/2020The Nonantibiotic Macrolide EM900 Attenuates House Dust Mite-Induced Airway Inflammation in a Mouse Model of Obesity-Associated Asthma.
10/2019Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process.
1/2018Anti-Inflammatory Effects of EM900 on Cultured Human Nasal Epithelial Cells.
1/2016Non-antibiotic 12-membered macrolides: design, synthesis and biological evaluation in a cigarette-smoking model.
1/2016Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.
10/2015The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells.
10/2015Macrolides Promote CCL2-Mediated Macrophage Recruitment and Clearance of Nasopharyngeal Pneumococcal Colonization in Mice.
8/2015Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium.
3/2014Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshiaki Sunazuka Research Topics

Disease

9Inflammation (Inflammations)
01/2022 - 01/2006
6Infections
01/2022 - 06/2010
6Neoplasms (Cancer)
08/2020 - 11/2002
5Asthma (Bronchial Asthma)
01/2020 - 05/2009
5Human Influenza (Influenza)
10/2019 - 07/2002
5Diffuse panbronchiolitis
01/2016 - 05/2004
3Pulmonary Fibrosis (Fibrosing Alveolitis)
03/2008 - 06/2004
2Rhinosinusitis
01/2018 - 08/2015
2Chronic Obstructive Pulmonary Disease (COPD)
01/2016 - 10/2015
2Sinusitis
01/2016 - 01/2011
1Paralysis (Palsy)
03/2022
1Hepatitis B
01/2022
1Mitochondrial Diseases (Mitochondrial Disease)
01/2022
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2022
1Obesity
01/2020
1Virus Diseases (Viral Diseases)
01/2020
1Hypothermia
10/2019
1Arthritis (Polyarthritis)
01/2019
1Mastitis
07/2017
1Schistosomiasis (Bilharziasis)
05/2017
1Malaria
07/2016
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2016
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2016
1Pneumococcal Infections
10/2015
1Pneumonia (Pneumonitis)
03/2014
1Disease Progression
03/2014
1Lung Diseases (Lung Disease)
06/2013
1Falciparum Malaria (Plasmodium falciparum Malaria)
04/2013
1Shock
03/2009
1Acquired Immunodeficiency Syndrome (AIDS)
08/2008
1Cystic Fibrosis (Mucoviscidosis)
08/2008
1Systemic Scleroderma (Systemic Sclerosis)
03/2008
1Neuroblastoma
02/2008
1Alzheimer Disease (Alzheimer's Disease)
02/2008

Drug/Important Bio-Agent (IBA)

17MacrolidesIBA
01/2020 - 05/2004
7Pharmaceutical PreparationsIBA
10/2019 - 04/2013
6Anti-Bacterial Agents (Antibiotics)IBA
01/2020 - 03/2014
5CytokinesIBA
01/2020 - 11/2002
4EM703IBA
06/2013 - 06/2004
3Erythromycin (Erycette)FDA LinkGeneric
01/2019 - 03/2008
3ChitinasesIBA
06/2013 - 05/2009
3VaccinesIBA
06/2010 - 07/2002
3Bleomycin (Blenoxane)FDA LinkGeneric
03/2008 - 06/2004
2Ivermectin (Mectizan)FDA Link
03/2022 - 05/2017
2Antimalarials (Antimalarial Agents)IBA
08/2020 - 04/2013
2Proteins (Proteins, Gene)FDA Link
10/2019 - 10/2015
2Clarithromycin (Biaxin)FDA LinkGeneric
01/2016 - 03/2014
2Interleukin-6 (Interleukin 6)IBA
10/2015 - 11/2002
2pinellic acidIBA
03/2003 - 07/2002
1Glutamic Acid (Glutamate)FDA Link
03/2022
1AnthelminticsIBA
03/2022
1Chloride Channels (Chloride Channel)IBA
03/2022
1avermectinIBA
03/2022
1exophillic acidIBA
01/2022
1Imiquimod (Aldara)FDA LinkGeneric
01/2022
1InflammasomesIBA
01/2022
1nanaomycin EIBA
01/2022
1Superoxides (Superoxide)IBA
08/2020
1Singlet OxygenIBA
08/2020
1Reactive Oxygen Species (Oxygen Radicals)IBA
08/2020
1Poly I-CIBA
01/2020
1Neuraminidase (Sialidase)IBA
10/2019
1Azithromycin (Zithromax)FDA LinkGeneric
10/2019
1Biological ProductsIBA
09/2019
1Ghrelin ReceptorsIBA
01/2019
1Iodoacetic AcidIBA
01/2019
1TylosinIBA
07/2017
1futalosineIBA
09/2016
1siamycin IIBA
09/2016
1Chloroquine (Aralen)FDA LinkGeneric
07/2016
1Gefitinib (Iressa)FDA Link
01/2016
1Therapeutic UsesIBA
01/2016
1Viral RNAIBA
10/2015
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
10/2015
1NF-kappa B (NF-kB)IBA
10/2015
1InterleukinsIBA
10/2015
1Messenger RNA (mRNA)IBA
10/2015
1LipopolysaccharidesIBA
08/2015
1SpiramycinIBA
03/2014
1Josamycin (EN 141)IBA
03/2014
1Hypochlorous Acid (Hypochlorite)IBA
03/2014
1Peroxidase (Myeloperoxidase)IBA
03/2014
11-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA
06/2013
1Environmental Pollutants (Pollutants, Environmental)IBA
06/2013
1Vehicle Emissions (Emissions, Vehicle)IBA
06/2013
1AntioxidantsIBA
06/2013
1borrelidinIBA
04/2013
1argifinIBA
05/2009
1InsecticidesIBA
05/2009
1Anti-HIV Agents (AIDS Drugs)IBA
08/2008
1CollagenIBA
03/2008
1AcetylcholinesteraseIBA
02/2008
1lactacystinIBA
02/2008
1TNF-Related Apoptosis-Inducing LigandIBA
09/2007
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2007
1cycloanthranilylprolineIBA
09/2007

Therapy/Procedure

7Therapeutics
01/2018 - 05/2004
3Oral Administration
01/2016 - 07/2002
1Conservative Treatment
01/2018
1Drug Therapy (Chemotherapy)
01/2016